# Association of hypoglycemic agents with the risk of immune checkpoint inhibitor-induced pneumonitis in patients with type 2 diabetes

Source: [Medical research : nature.com subject feeds](https://www.nature.com/articles/s41598-026-80275-w) · 2026-11-12 · Medicine
Page: https://themorning.science/story/association-of-hypoglycemic-agents-with-the-risk-of-immune-checkpoint-inhibitor-bc1f89ce85077d28
Kind: research · Impact: low

## In brief

- A study titled "Association of hypoglycemic agents with the risk of immune checkpoint inhibitor-induced pneumonitis in patients with type 2 diabetes" appeared in a nature.com subject feed dated 2026-11-12.
- The provided source has no summary, so the study's findings cannot be confirmed from the available material.
- The study examines the link between diabetes medications and pneumonitis in patients receiving immune checkpoint inhibitors.

## Why it matters

Clinicians and patients with type 2 diabetes who receive checkpoint inhibitor cancer therapy may care whether diabetes medications are associated with pneumonitis risk, but the reported results are not available in the provided sources.

## Coverage

- [Association of hypoglycemic agents with the risk of immune checkpoint inhibitor-induced pneumonitis in patients with type 2 diabetes](https://www.nature.com/articles/s41598-026-80275-w) — Medical research : nature.com subject feeds, 2026-11-12

Tags: immunotherapy, type 2 diabetes, pneumonitis, hypoglycaemic agents, drug safety

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science